Last edition
News about "onCARlytics and Carteyva Combination "
Imugene and JW Therapeutics have partnered to explore a new combination for refractory solid tumours, pairing Imugene’s onCARlytics (CF33-CD19) oncolytic virus with JW’s CD19 CAR-T therapy, Carteyva. The collaboration will begin with pre-clinical studies and advance to a Phase 1 investigator-initiated trial in China targeting hard-to-treat cancers.
OnCARlytics And Carteyva Combination | 01/12/2025 | By Dineshwori | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members